Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
  1. Home
  2. Stock
  3. GERN
GERN logo

GERN Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Geron Corp (GERN) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.660
1 Day change
1.84%
52 Week Range
2.010
Analysis Updated At
2026/03/06
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Geron Corp (GERN) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows weak technical indicators, limited positive catalysts, and no recent significant news or events to drive immediate growth. While hedge funds are increasing their positions, the company's financials, although improving, remain negative. It is better to hold off on investing in this stock until stronger signals or catalysts emerge.

Technical Analysis

The MACD histogram is negative and expanding, indicating bearish momentum. RSI is at 28.745, suggesting the stock is nearing oversold territory but not providing a clear signal. Moving averages are converging, showing no strong trend. Key support is at 1.457, and the stock is trading close to this level, with resistance at 1.892.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
3
Buy
7

Positive Catalysts

  • Hedge funds are significantly increasing their positions, with a 226.92% increase in buying over the last quarter. Financials show YoY improvements in revenue, net income, and EPS.

Neutral/Negative Catalysts

  • No recent news or significant insider activity. Gross margin dropped YoY. The stock has a low probability of significant short-term price increases based on candlestick pattern analysis. Analyst price target was lowered from $4 to $3.

Financial Performance

In Q4 2025, revenue increased by 1.01% YoY to $48.02M. Net income improved by 22.85% YoY but remains negative at -$31.14M. EPS improved by 25% YoY to -$0.05. Gross margin decreased slightly to 97.28%, down 1.09% YoY.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

TD Cowen analyst Tara Bancroft maintains a Buy rating but lowered the price target from $4 to $3, reflecting tempered expectations ahead of Q4 results.

Wall Street analysts forecast GERN stock price to rise
4 Analyst Rating
Wall Street analysts forecast GERN stock price to rise
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 1.630
sliders
Low
4
Averages
4
High
4
Current: 1.630
sliders
Low
4
Averages
4
High
4
TD Cowen
Tara Bancroft
Buy
downgrade
$4 -> $3
AI Analysis
2026-01-29
Reason
TD Cowen
Tara Bancroft
Price Target
$4 -> $3
AI Analysis
2026-01-29
downgrade
Buy
Reason
TD Cowen analyst Tara Bancroft lowered the firm's price target on Geron to $3 from $4 and keeps a Buy rating on the shares. The firm updated its model ahead of Q4 results.
Goldman Sachs
initiated
$1
2025-07-10
Reason
Goldman Sachs
Price Target
$1
2025-07-10
initiated
Reason
Goldman Sachs resumed coverage of Geron with a Sell rating and $1 price target, which suggests 31% downside. The initial launch of the company's lead product and first commercial drug, Rytelo, has disappointed, and the near-term trajectory for the launch will be modest, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for GERN
Unlock Now

People Also Watch